Figure 6.
Teng reduce leukemia burden in vivo. NSG mice were inoculated with BCP-ALL (Pts 16, 18, and 19) and T-ALL (Pt 22) samples, before being treated with Teng and T cells. (A) Engraftment levels in PB, monitored weekly by flow cytometry. Gray boxes represent duration of treatment. Data in PB graphs represent mean ± SD (n = 3-4 mice per treatment condition). (B) Proportion of ROR1+ and CD19+ cells in BM at termination. (C) IFN-γ levels in murine plasma at termination. Bars represent mean ± SD (n = 3-4).

Teng reduce leukemia burden in vivo. NSG mice were inoculated with BCP-ALL (Pts 16, 18, and 19) and T-ALL (Pt 22) samples, before being treated with Teng and T cells. (A) Engraftment levels in PB, monitored weekly by flow cytometry. Gray boxes represent duration of treatment. Data in PB graphs represent mean ± SD (n = 3-4 mice per treatment condition). (B) Proportion of ROR1+ and CD19+ cells in BM at termination. (C) IFN-γ levels in murine plasma at termination. Bars represent mean ± SD (n = 3-4).

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal